AbbVie announced on Wednesday it will spend $1.4 billion building a new pharmaceutical manufacturing campus in Durham, North Carolina — its biggest single-site investment ever.
We announced a $1.4B investment to build a new pharmaceutical manufacturing site in Durham, N.C., creating 734 new jobs & progressing against our $100B commitment to U.S. R&D and capital investment, including manufacturing, over the next decade. Read more: https://t.co/ZGI4N1uneW pic.twitter.com/ZqQwYmQOcO
— AbbVie (@abbvie) April 22, 2026
The 185-acre campus will sit near Research Triangle Park and serve as AbbVie’s U.S. center of excellence for small volume parenteral (SVP) manufacturing. These are sterile injectable medicines — vials, syringes and prefilled cartridges — used to treat conditions across immunology, neuroscience and oncology.
This is AbbVie’s first major footprint in North Carolina.
Construction is set to begin later this year, with the full campus expected to be operational by the end of 2028. The first phase includes manufacturing plants, labs, a warehouse, office space and employee wellness facilities.
AbbVie plans to hire 734 full-time employees over four years — engineers, scientists, manufacturing operators and lab technicians. The build will also support more than 2,000 construction jobs during development.
CEO Robert A. Michael said the investment “strengthens our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina.”
The Durham campus is one piece of a much larger picture. AbbVie has pledged to spend roughly $100 billion on U.S. research, development and manufacturing over the next decade.
In the past 12 months alone, the company has committed over $2.2 billion to U.S. manufacturing projects across North Carolina, Illinois, Arizona and Massachusetts.
Back in February, AbbVie announced a $380 million investment to build two active pharmaceutical ingredient manufacturing facilities at its North Chicago, Illinois campus, focused on neuroscience and obesity medicines.
The Durham site adds to that momentum.
AbbVie picked the Research Triangle Park area for its skilled regional workforce and room for future expansion.
North Carolina Governor Josh Stein welcomed the move, calling the state “the premier location for biopharmaceutical companies to do business.”
When complete, the campus will supply medicines both domestically and internationally, acting as a central hub for AbbVie’s injectable drug production in the U.S.
AbbVie currently employs around 29,000 people across the U.S., including more than 6,000 at its domestic manufacturing sites. With this announcement, the company’s total U.S. job creation commitment in the past year now exceeds 1,300 new positions across four states.
The campus will also integrate AI and advanced manufacturing technologies into its operations — a detail AbbVie highlighted in its announcement.
The project represents AbbVie’s first entry into North Carolina as a manufacturing state, and the company says the site has been designed with future pipeline growth in mind.
The post AbbVie (ABBV) Stock Jumps On $1.4 Billion North Carolina Campus Announcement appeared first on CoinCentral.
